Abstract All Streptococcus pneumoniae strains isolated from paediatric clinical samples at Heraklion University General Hospital in the 10-year period 2000-2009 were tested for serotype and susceptibility to antimicrobials. Among a total of 258 strains, 159 were isolated in the 5-year period 2000-2004, before the introduction of the heptavalent pneumococcal conjugate vaccine (PCV7), and 99 in the post-PCV7 5-year period [2005][2006][2007][2008][2009]. The prevalence of PCV7-included serotypes decreased in the post-PCV7 period (p= 0.0002), but an increase was observed for serotypes 7F (p= 0.002) and 19A (p=0.004). Pan-susceptibility rates and susceptibility to cotrimoxazole increased in the post-PCV7 period (p=0.01 and p=0.008, respectively), but serotype 19A emerged as a contributor to multi-resistance (p=0.007). PCV7 was followed by decreased S. pneumoniae resistance and prevalence of vaccine-related serotypes but increased prevalence of serotypes 7F and 19A. Continuing surveillance is required after the recent introduction of PCV10 and PCV13.
Introduction
The introduction of heptavalent pneumococcal conjugated vaccine (PCV7) has resulted in a decrease of pneumococcal infections, but reports on the increase of potentially invasive and resistant strains necessitate the surveillance of Streptococcus pneumoniae isolates [1] . Information on the impact of the implementation of PCV7 into immunisation programmes comes mainly from the USA and Canada, and to a lesser degree from Europe [2] [3] [4] [5] [6] [7] [8] . In Greece, PVC7 became available in 2004 and was introduced for all children younger than 5 years of age in January 2006. Vaccination compliance has been high nationwide, with reported rates of up to 98% [5] . Crete is the southernmost point of Europe and the second major island in the Eastern Mediterranean basin. In this study, we investigated the circulating S. pneumoniae serotypes and the trends in antimicrobial susceptibility of clinical isolates from children pre-and post the PCV7 introduction.
Patients and methods
This study included all paediatric S. pneumoniae specimens which were cultured, serotyped and tested for susceptibility to antimicrobials in the Laboratory of Microbiology at the University General Hospital, Heraklion, Greece, for the 10-year period January 2000 through December 2009. The hospital is the referral centre for the island of Crete, with a coverage population of 631,000, of whom 130,000 are children aged less than 14 years. Invasive pneumococcal disease isolates were recovered from blood or cerebrospinal fluid (CSF), and otitis media isolates from middle ear fluid. One isolate per patient was identified and tested. Samples were immediately plated after collection on chocolate agar and Columbia agar plates (Becton Dickinson, Sparks, MD, USA) supplemented with 5% sheep blood and incubated at 35°C in an atmosphere of 5% CO 2 in air for 24-72 h.
For blood cultures, the automated BacT/Alert system (bioMérieux Inc., Durham, NC, USA) was used. S. pneumoniae isolates were identified on the basis of colonial and microscopic morphology, haemolytic activity on sheep blood agar medium, optochin susceptibility and bile solubility.
All isolates were serotyped by the Quellung reaction using pooled and selected factor antisera from Statens Serum Institut (SSI, Copenhagen, Denmark). Nineteen antimicrobial agents, including seven β-lactams (penicillin, cefuroxime, cefotaxime, ceftriaxone, cefepime, imipenem and meropenem), three macrolides (erythromycin, clarithromycin and roxithromycin), four quinolones (ciprofloxacin, moxifloxacin, levofloxacin and sparfloxacin), clindamycin, cotrimoxazole, tetracycline, chloramphenicol and vancomycin, were assayed by Etest (AB Biodisk, Solna, Sweden). The results were interpreted according to the 2008 Clinical and Laboratory Standards Institute (CLSI) criteria. S. pneumoniae ATCC 6305 (penicillin-sensitive) and S. pneumoniae ATCC 49619 (penicillin-resistant) were used as control strains. Data were compared using Fisher's exact probability test. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Statistical significance was set at two-tailed p <0.05.
Results and discussion
A total of 258 clinical isolates were collected from 140 boys and 118 girls, with age ranging from 15 days to 14 years (mean, 3.16; median, 2.0). Isolates represented blood (23), cerebrospinal fluid (5), middle ear fluid (39), nasopharyngeal swabs (132), ocular secretions (43), sputum (6) , bronchoalveolar lavage (6) and pus (4 In the vaccine period, a decrease was observed for serotypes included in the PCV7 (Table 1) , but an increase was observed for the PCV10-included 7F, the PCV13-included 19A and for the total of serotypes not included in PCV7, PCV10 or PCV13 (25 vs. 21 isolates; 25.3% vs. 13.2%; p=0.019; OR 2.22, 95% CI 1.16-4.23). Coverage by PCV7 was 69.2% for the pre-vaccine period, but coverage for the vaccine period by the 7-valent, 10-valent and 13-valent PCVs were 45.5, 56.6 and 75.5% of clinical isolates, respectively. Prevailing serotypes for invasive infection were 19F (3/10) in the pre-vaccine and 7F (7/18) in the vaccine period. The prevailing serotype for otitis media was 19F both in the pre-vaccine (4/15) and in the vaccine period (10/24). Non-susceptibility rates were significantly lower in the vaccine than in the pre-vaccine period for cotrimoxazole (20.2% vs. 36.5%; p=0.008; OR 0.44; 95% CI 0.24-0.79) and near-significantly lower for erythromycin (p=0.081). There were 124/258 isolates (48.1%) susceptible to all antibacterials tested, and this pan-susceptibility was more common in the vaccine than in the pre-vaccine period (58/99 vs. 66/159; 58.6% vs. 41.5%; p=0.01, OR 1.99, 95% CI 1.20-3.32). The overall high-level resistance rates were 17.1% for penicillin, 26.4% for cefuroxime and 0% for cefotaxime and ceftriaxone. Among 91 isolates resistant to erythromycin, phenotypes M, cMLS B and iMLS B were detected in 62, 25, and four isolates, respectively. Invasive and non-invasive isolates had similar susceptibility patterns. Ocular strains were more penicillin-sensitive than invasive and middle ear strains (72.1% vs. 52.2%; p=0.01; OR 2.36, 95% CI 1.04-5.47). Ultra-high penicillin resistance (minimum inhibitory concentration [MIC] 4 μg/mL) was observed in 11/258 isolates (4.28%), of which nine were serotyped as 19F. Ciprofloxacin MIC of ≥3 mg/L was observed in 13/258 isolates. Among common serotypes in the vaccine period, serotype 19A was often non-susceptible to penicillin, cefuroxime and erythromycin (84.6, 69.2 and 76.9%, respectively), but serotype 7F was sensitive to all antimicrobials tested. Multi-resistance (penicillin, erythromycin, cotrimoxazole and tetracycline) rates were similar in the pre-vaccine and the vaccine period (13.8 and 15.2%, respectively). The principal multi-resistant serotype in the pre-vaccine period was 19F (16/22, 72.7% deceasing to 7/15, 46.7% in the vaccine period). Serotype 19A was a significant contributor to multiresistant strains in the vaccine as compared to the pre-vaccine period (5/15 vs. 0/22, 33.3% vs. 0%; p=0.007).
The introduction and the high uptake of PCV7 in the study area and the ability to centrally test clinical isolates provided the tools to investigate the effects of vaccine introduction in a well-defined population. Limitations of this study include the small cohort of isolates and the retrospective design, which did not allow for the investigation of factors potentially affecting seroprevalence and susceptibility besides the introduction of PCV7. The study included all clinical isolates rather than invasive strains or nasopharyngeal carriage samples alone, and this limitation did not allow for a reliable comparison of the PCV7 efficacy results to previously reported findings. Serotypes of S. pneumoniae isolates were similar to these reported elsewhere in Greece [2] [3] [4] [5] [6] . In the pre-vaccine era, PCV7 coverage was 69.2% in the study area, but following a decrease in vaccine-included serotypes, coverage by PCV7 in Crete dropped to 36.5% during the last three study years. Invasive disease and otitis media isolates appeared to be more common in the vaccine period, but it is questionable whether this increase should be attributed to the small sample size or to increased awareness of pneumococcal disease following the introduction of PCV7, rather than to a real increase in disease. Reports on invasive pneumococcal disease due to non-PCV7 serotypes have been controversial [7, 8] . Non-susceptibility rates of S. pneumoniae isolates were similar to rates already reported elsewhere in Greece [3, 4] . No resistance was observed to fluoroquinolones, and third-generation cephalosporins were active throughout the study. The introduction of PCV10 and PCV13 will reasonably necessitate continued monitoring of S. pneumoniae seroprevalence, replacement of isolates by non-vaccine serotypes and susceptibility patterns.
